CD8 (cluster of differentiation 8)

P1/2, N=215, Active, not recruiting, ANRS, Emerging Infectious Diseases | Recruiting --> Active, not recruiting

Consistently, a risk-score based on the NETosis-MAPK signaling interaction is significantly associated with poorer survival in human PDACs. This study thus provides a new venue for overcoming resistance to strategies targeting KRAS signaling.

The immune microenvironment, characterized by CD8 + and CD68 + cell density and PDL1 expression, together with patient age, appears to influence clinical outcomes in HMSC. These findings suggest that a subset of HMSC patients, particularly those with an inflamed tumor microenvironment, may be candidates for PDL1-targeted immunotherapy.

Further investigations reveal that Gsα upregulates expression of CD86, CCR5, Il1b and Nos2, and inhibits CD206 and Il10 expression, which facilitates antitumoral activity of TAMs. Mechanistically, Gsα promotes M1 polarization of TAMs via upregulating phosphorylation of ERK, p38 and JNK in MAPK signaling pathway.

Pharmacological antagonism of CXCL12/CXCR4 axis potentiated the immunotherapy efficacy in orthotopic TNBC mouse models. In conclusion, this study highlights a HTRA1+ macrophage subpopulation that can limit T cell infiltration and immunotherapy efficacy via the CXCL12/CXCR4 axis, which offers new leads to improve immunotherapeutic interventions in TNBC.

Notably, both adoptive transfer of Nano ZSA-51D-reprogrammed neutrophils and systemic Nano ZSA-51D treatment synergizes with α-PD1 therapy to achieve complete remission of colon tumors through neutrophil- and CD8+ T cell-dependent mechanisms, with potent efficacy also validated in otherwise immune-resistant pancreatic cancer models. Our findings establish a therapeutic strategy to reprogram HSPCs toward antitumor neutrophils, highlighting the potential of targeting early hematopoiesis to rewire neutrophil fate in cancer immunotherapy.

T cells also affect lesion clearance by microglia and astrocytic BDNF expression; however, their effect is stronger on microglia. These findings provide novel insights into the immune regulation of brain tissue regeneration.

Co-expression of LAG-3, TIM-3, and IDO1 characterizes an immune-active but potentially exhausted microenvironment, particularly in never-smoking, never-drinking oral squamous cell carcinoma. This pattern may define an immunologically distinct subtype with possible relevance for combinatorial immunotherapy approaches.

Our findings provided basic evidence for immunotherapy efficacy in intimal sarcomas and identified potential molecular targets. Further studies involving larger case series are required to validate these results.

Functionally, co-culture assays showed that knockdown of CD70 in B-lymphoma cells reduced naive CD4+ and CD8+ T-cell subsets, whereas CD79BY197H transfected B-lymphoma cells enhanced tumor cell viability. Our findings comprehensively characterize FL/DLBCL and tFL molecularly, elucidating their distinct pathogenesis and rationalize CD70 and CD79B targeted immunotherapies.

Spegs and spems are associated with changes in the host immune response, characterized by an increased accumulation of Tfh in germinal centers. This finding is accompanied by the presence of IgE and IgG4 plasma cells in the lymph node and the perilesional area, suggesting parasite-associated immunomodulatory processes in echinococcosis.

In preclinical cancer models, intravenous administration of YbNano potentiated the efficacy of anti-PD-L1 therapy in B16F10 melanoma-bearing C57BL/6 mice and enhanced the therapeutic outcomes of doxorubicin or anti-PD-L1 treatment in suppressing lung metastasis in 4T1 breast cancer-bearing BALB/c mice. YbNano functions as a dual activator of cGAS/STING and TLR9, orchestrating dendritic cell activation and amplifying downstream innate and adaptive immune responses in tumor microenvironment. Collectively, these findings suggest that YbNano represents a rationally engineered, multifunctional nucleic acid-based immunotherapeutic agent with the potential to modulate the tumor microenvironment and to augment responses when used in combination cancer therapy.